-+ 0.00%
-+ 0.00%
-+ 0.00%

European Commission Approves Incyte's Minjuvi In Combination With Lenalidomide And Rituximab For Relapsed or Refractory Follicular Lymphoma

Benzinga·12/17/2025 16:23:02
Listen to the news
  • Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab is the first CD19- and CD20-dual-targeted immunotherapy combination regimen approved for eligible patients in Europe with relapsed or refractory FL
  • Patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide in the Phase 3 inMIND registration trial
  • In Western countries, including Europe, relapsed or refractory FL affects 2-4 out of every 100,000 people1

Incyte (NASDAQ:INCY) today announced that the European Commission (EC) has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy.